BCL2L12, a newly identified member of Bcl-2 family, contains a BH2 domain and a putative BH3 domain. It was found to be highly expressed in normal breast tissues, and was associated with favorable prognosis in breast cancer patients. Here, we reported that the mRNA levels of BCL2L12 and its transcript variant BCL2L12A could be upregulated upon cisplatin treatment in MDA-MB-231 breast cancer cells. Knockdown of BCL2L12 and BCL2L12A dramatically inhibited cisplatin-induced apoptosis. In contrast, ectopic expressions of each of the proteins promoted cisplatin-induced apoptosis. These results indicated that decreased expressions or loss of BCL2L12 and BCL2L12A may contribute to the cisplatin resistance in breast cancer patients. Furthermore, we found that cisplatin-induced downregulation of beta-catenin was partially suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231 cells, which indicated that knockdown of these two proteins may stabilize beta-catenin in cisplatin-induced apoptosis. In short, we proposed that BCL2L12 and BCL2L12A may play an important role in cisplatin-induced apoptosis in MDA-MB-231 breast cancer cells.

Purpose This study aims to optimize the structure of gold-sputtered U-shaped plastic fiber sensors. Design/methodology/approach A group of U-shaped Au-sputtered plastic optical fiber sensing probes with polishing angles of 45°, 90° and 135° is prepared. Findings The experimental results show that the spectral response and sensitivity of the sensor at 45°polishing angle is twice that of the sensor at 90°. Research limitations/implications Due to the limitations of laboratory temperature and equipment, the overall effect has not reached the ideal, but the expected effect has been obvious. Experiments also optimize the sensor. Practical implications Optical fiber sensing has always been an indispensable part of various fields. Social implications Sensor optimization is of great help to the progress of technology and the development of science and technology. Originality/value The authors have no conflicts of interest to disclose.

No abstract

No abstract